B7-33 vs Bergamot Extract
A side-by-side research comparison of B7-33 and Bergamot Extract across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | B7-33 | Bergamot Extract |
|---|---|---|
| Full name | B7-33 (Relaxin Peptide Analog) | Citrus Bergamia Polyphenol Extract |
| Category | Cardiovascular | Cardiovascular |
| Status | Research peptide (preclinical) | Dietary supplement |
| Mechanism | Selectively activates the relaxin receptor RXFP1 pathway, biasing signaling toward anti-fibrotic effects. It reduces collagen deposition and promotes healthy tissue remodeling in heart, lung, and kidney models without some downsides of full-length relaxin. | Polyphenolic flavonoids (brutieridin, melitidin) inhibit HMG-CoA reductase (same target as statins). Activates AMPK for fat oxidation. Reduces PCSK9 expression. Improves LDL receptor recycling for enhanced cholesterol clearance. |
| Molecular weight | ~3.3 kDa | Complex polyphenol mixture |
| Half-life | Short (peptide) | ~4-6 hours |
| Bioavailability | Injection (research) | ~15-25% (polyphenol absorption) |
| Typical dose | Not established for humans | 500-1000 mg standardized extract |
| Frequency | Research only | Daily with meals |
| Route | Injection (research) | Oral capsule |
B7-33 reported benefits
- Anti-fibrotic effects (preclinical)
- Cardiac and organ protection (research)
- Healthy tissue remodeling
- Relaxin-pathway (RXFP1) biased signaling
Bergamot Extract reported benefits
- LDL cholesterol reduction (20-35%)
- HDL improvement
- Blood glucose stabilization
- Triglyceride reduction
- Statin alternative/adjunct
- No muscle pain side effects
Related comparisons
Research and educational reference only. Not medical advice.